Compare BPYPO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BPYPO | GNLX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 110.4M |
| IPO Year | 2012 | 2022 |
| Metric | BPYPO | GNLX |
|---|---|---|
| Price | $14.62 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 22.2K | ★ 266.4K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.08 | $2.29 |
| 52 Week High | $16.26 | $8.54 |
| Indicator | BPYPO | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 32.19 | 44.65 |
| Support Level | $14.62 | $2.34 |
| Resistance Level | $15.34 | $2.86 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 28.56 | 39.29 |
Brookfield Property Partners LP owns and operates in North America, Europe, Australia, and Brazil. The company focuses on being an owner and operator of real estate, providing investors with diversified exposure to some of the iconic properties and acquiring high-quality assets at a discount to replacement cost or intrinsic value. Its operating segment includes Core Office, Core Retail, LP Investments, and Corporate Segments. The company operates in various sectors such as the office sector, retail sector, industrial, multifamily, hospitality, triple net lease, and corporate sector. It generates a majority of revenue from the LP Investments segment.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.